Zhongli Cai
Toronto, ON M5S3M2, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 45 publications
Panitumumab labeled with Auger electron-emitting 197gHg/197mHg: cytotoxicity on human breast cancer cells and tumour and normal tissue uptake in mice with EGFR-overexpressing breast cancer xenografts.
Journal: EJNMMI radiopharmacy and chemistry
Published: February 06, 2026
Treatment of Human Glioblastoma Multiforme in NRG Mice by Convection-Enhanced Delivery of EGFR-Targeted or Nontargeted Auger Electron-Emitting 197gHg-Labeled Gold Nanoparticles.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: December 01, 2025
Radiopharmaceutical kit to prepare Copper-64 labelled porphyrin-lipid nanoparticles for radiotracer imaging studies in cancer patients.
Journal: European journal of nuclear medicine and molecular imaging
Published: May 15, 2025
Auger electron-emitting EGFR-targeted and non-targeted [197Hg]Hg-gold nanoparticles for treatment of glioblastoma multiforme (GBM).
Journal: EJNMMI radiopharmacy and chemistry
Published: May 01, 2025
Synthesis and Characterization of Thallium-Texaphyrin Nanoparticles and Their Assessment as Potential Delivery Systems for Auger Electron-Emitting 201Tl to Cancer Cells.
Journal: Molecular pharmaceutics
Published: December 16, 2024
Preclinical Comparison of [111In]In- and [225Ac]Ac-DOTA-Trastuzumab IgG, F(ab')2 and Fab for Theranostic SPECT/CT Imaging and α-Particle Radioimmunotherapy of HER2-Positive Human Breast Cancer.
Journal: Molecular pharmaceutics
Published: December 12, 2024
Convection-enhanced delivery of [177Lu]Lu-labeled gold nanoparticles combined with anti-PD1 checkpoint immunotherapy improves the survival of immunocompetent C57BL/6J mice with orthotopic GL261 murine glioma tumors.
Journal: Nuclear medicine and biology
Published: September 30, 2024
Radiation nanomedicines for cancer treatment: a scientific journey and view of the landscape.
Journal: EJNMMI radiopharmacy and chemistry
Published: January 31, 2024
Bispecific radioimmunoconjugates exploit receptor heterogeneity for positron emission tomography of tumors expressing HER2 and/or EGFR.
Journal: iScience
Published: November 20, 2023
Adjuvant Auger Electron-Emitting Radioimmunotherapy with [111In]In-DOTA-Panitumumab in a Mouse Model of Local Recurrence and Metastatic Progression of Human Triple-Negative Breast Cancer.
Journal: Molecular pharmaceutics
Published: November 20, 2023
[225Ac]Ac- and [111In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts.
Journal: EJNMMI radiopharmacy and chemistry
Published: June 14, 2023
Relative Biological Effectiveness (RBE) of [64Cu]Cu and [177Lu]Lu-NOTA-panitumumab F (ab')2 radioimmunotherapeutic agents vs. γ-radiation for decreasing the clonogenic survival in vitro of human pancreatic ductal adenocarcinoma (PDAC) cells.
Journal: Nuclear medicine and biology
Published: February 26, 2023
Last Updated: 09/26/2026